Cited by 1,192Diabetes Treatment and ManagementDiabetes Management and ResearchHeart Failure Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Open access

Buse, John B., Wexler, Deborah J., Tsapas, Apostolos, Rossing, Peter, Mingrone, Geltrude, Mathieu, Chantal, D’Alessio, David A., Davies, Melanie J.·2020·Diabetes Care

DOI 10.2337/dci19-0066PMC PMC6971782

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dci19-0066

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
Result
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citation
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084

Show all 21 references

Sorted by citations

Items 501–600 of 1,000

Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia
Gelhorn, H. L., Boye, K. S., Shalhoub, H., Matza, L. S., Jordan, J. B., Alhammad, A., Anand, S. B., Ekhzaimy, A. A., & Strizek, A. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s265126 · Cited by 11
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta‐analysis
Liao, X., Li, W., Peng, Z., Yu, H., & Tan, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13588 · Cited by 10
Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013–2019
Wikström, K., Lamidi, M., Rautiainen, P., Tirkkonen, H., & Laatikainen, T. K. (2022) · Diabetic Medicine · doi:10.1111/dme.14866 · Cited by 10
Protective Effects of Cinnamic Acid Against Hyperglycemia Induced Oxidative Stress and Inflammation in HepG2 Cells
Yazdi, M., Nafari, A., Azadpour, M., Alaee, M., Moradi, F. H., Choghakhori, R., Hormozi, M., & Ahmadvand, H. (2023) · Reports of Biochemistry and Molecular Biology · doi:10.61186/rbmb.12.1.1 · Cited by 10
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
Bernfort, L., Husberg, M., Wiréhn, A.-B., Rosenqvist, U., Gustavsson, S., Karlsdotter, K., & Levin, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00840-y · Cited by 10
Iranian Endocrine Society Guidelines for Screening, Diagnosis, and Management of Gestational Diabetes Mellitus
Valizadeh, M., Hosseinpanah, F., Tehrani, F. R., Abdi, H., Mehran, L., Hadaegh, F., Amouzegar, A., Sarvghadi, F., Azizi, F., & Iranian Endocrine Society Task Force (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.107906 · Cited by 10
Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies
Farsang, C., Dézsi, C. A., Brzozowska-Villatte, R., Champvallins, M. D., Глезер, М. Г., & IuA, K. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01619-8 · Cited by 10
The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis
Patoulias, D., Papadopoulos, C. E., Siskos, F., Stavropoulos, K., & Doumas, M. N. (2021) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000537 · Cited by 10
Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study
Bidulka, P., O’Neill, S., Basu, A., Wilkinson, S., Silverwood, R. J., Charlton, P., Briggs, A. H., Adler, A., Khunti, K. K., Tomlinson, L. A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046912 · Cited by 10
Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
Franchi, M., Pellegrini, G., Avogaro, A., Buzzetti, G., Candido, R., Cavaliere, A., Consoli, A., Marzona, I., Mennini, F. S., Palcic, S., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003991 · Cited by 11
A randomized clinical trial of genetic testing and personalized risk counselling in patients with type 2 diabetes receiving integrated care -The genetic testing and patient empowerment (GEM) trial
Ronald, C. W., Xie, F., Lim, C. K. P., Lau, E. S. H., Luk, A. O. Y., Ozaki, R., Cheung, G. P. Y., Lee, H. M., Ng, A. C. W., Li, H. W., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109969 · Cited by 10
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes ( TROPHIES ): Patient disposition, clinical characteristics and treatment persistence at 12 months
Guerci, B., Giorgino, F., Sapin, H., Boye, K. S., Lebrec, J., Federici, M. O., Heitmann, E., Dib, A., Füchtenbusch, M., & García‐Pérez, L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14823 · Cited by 10
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
Seo, D. H., Suh, Y. J., Cho, Y., Ahn, S. H., Seo, S., Hong, S., Lee, Y., Choi, Y. J., Lee, E. J., & Kim, S. H. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.9.825 · Cited by 10
Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care
Morieri, M. L., Longato, E., Camillo, B. D., Sparacino, G., Avogaro, A., & Fadini, G. P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01712-4 · Cited by 10
Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
González‐Pérez, A., Vizcaya, D., Sáez, M. E., Lind, M., & Rodríguez, L. A. G. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003072 · Cited by 12
GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
Romera, I., Santos, M. R., Artola, S., Fernández, C. S., & Conget, I. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02442-z · Cited by 10
Novel management of diabetes in kidney transplantation
Ong, S., & Rhee, C. M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000665 · Cited by 10
Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
Schnaars, Y., Gaikwad, S., Gottwald‐Hostalek, U., Klingberg, U., Vadla, H. K. C., & Prathap, V. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01269-1 · Cited by 10
Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials
Yates, T., Sargeant, J. A., King, J. A., Henson, J., Edwardson, C. L., Redman, E., Gulsin, G. S., Brady, E. M., Ahmad, E., Stensel, D. J., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0888 · Cited by 9
Self-citation
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Heller, S. R., Raposo, J. F., Tofé, S., Hanif, W., Schroner, Z., Down, S., & Blevins, T. (2022) · Clinical Diabetes · doi:10.2337/cd22-0016 · Cited by 9
Comprehensive machine learning models for predicting therapeutic targets in type 2 diabetes utilizing molecular and biochemical features in rats
Matboli, M., Al-Amodi, H. S. A. B., Khaled, A., Khaled, R., Roushdy, M. M. S., Ali, M., Diab, G. I., Elnagar, M. F., Elmansy, R. A., TAhmed, H. H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1384984 · Cited by 10
Psychosocial factors influencing dietary management in patients with type 2 diabetes and healthy adults: an ecological momentary assessment approach
Saito, J., & Kumano, H. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1464542 · Cited by 10
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes
Saeed, A., Mulukutla, S. R., Thoma, F. W., Lemon, L. S., Koczo, A., Reís, S. E., Marroquin, O. C., & Kip, K. E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-00775 · Cited by 9
Glucose‐lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology
Hong, T., Su, Q., Li, X., Shan, Z., Chen, L., Peng, Y., Chen, L., Yan, L., Bao, Y., Lyu, Z., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3416 · Cited by 9
The Effect of Metformin on Self-Selected Exercise Intensity in Healthy, Lean Males: A Randomized, Crossover, Counterbalanced Trial
Pilmark, N. S., Petersen-Bønding, C., Holm, N. F. R., Johansen, M. Y., Pedersen, B. K., Hansen, K. B., & Karstoft, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.599164 · Cited by 9
Metabolic Impacts of Food Oral Processing
Forde, C. G., & Stieger, M. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160622-00137 · Cited by 11
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 11
Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
Costa, J. D. O., Lin, J., Milder, T. Y., Greenfield, J. R., Day, R. O., STOCKER, S. L., Neuen, B. L., Havard, A., Pearson, S., & Falster, M. O. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15597 · Cited by 9
The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes—A Scientometric Investigation and Visualization Study
Pantea, I., Repanovici, A., & Andreescu, O. (2024) · Medicina · doi:10.3390/medicina60111761 · Cited by 9
Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results
Mody, R., Yu, M. B., Grabner, M., Boye, K. S., Teng, C., & Kwan, A. Y. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.011 · Cited by 9
Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people
Emmerton, D., & Abdelhafiz, A. H. (2021) · Hospital Practice · doi:10.1080/21548331.2021.1905414 · Cited by 9
Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
Sciannameo, V., Berchialla, P., Avogaro, A., Fadini, G. P., DARWIN-T2D Network, Consoli, A., Formoso, G., Grossi, G., Pucci, A., Sesti, G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01300-y · Cited by 9
A new Glucose-Responsive delivery system based on Sulfonamide-phenylboronic acid for subcutaneous insulin injection
Zhang, P., Ma, Q., He, D., Liu, G.-H., Tang, D., Liu, L., & Wu, J. (2021) · European Polymer Journal · doi:10.1016/j.eurpolymj.2021.110648 · Cited by 9
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
Araki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14536 · Cited by 12
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzı́k, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 9
Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras
Guarnotta, V., Radellini, S., Vigneri, E., Cernigliaro, A., Pantò, F., Scondotto, S., Almasio, P. L., Guercio, G., & Giordano, C. S. D. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259405 · Cited by 9
Isolated systolic hypertension and insulin resistance assessment tools in young and middle-aged Chinese men with normal fasting glucose: a cross-sectional study
Gu, Q., Meng, J., Hu, X. F., Ge, J., Wang, S. J., & Liu, X. (2022) · Scientific Reports · doi:10.1038/s41598-021-04763-x · Cited by 9
Novel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 11
Diabetic Ketoacidosis After Sodium–Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes
Visser, M. M., Mathieu, C., & Gillard, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0553 · Cited by 9
Self-citation
New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada
Bodoarca, R., Yeung, R. O., & Lau, D. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.04.004 · Cited by 9
Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
Jhalani, N. B. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02169-3 · Cited by 10
Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
Chai, S., Zhang, R., Zhang, Y., Carr, R. D., Zheng, Y., Rajpathak, S. N., & Yu, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935039 · Cited by 9
Correlation between glucose measurement parameters of continuous flash monitoring and HbA1c. Real life experience in Asturias
Alarcón, P. P., Felgueroso, C. A., Ares, J., Morales-Sánchez, P., Goitia, C. L., Escobedo, R. R., Rodríguez‐Rodero, S., Delgado, E., & Torre, E. L. M. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.08.001 · Cited by 9
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11
Evans, M., Chubb, B., Malkin, S. J. P., Berry, S., Lawson, J., & Hunt, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14892 · Cited by 9
Health Literacy Brisk Walking Exercise on Clinical Outcomes of Blood Sugar in Patients with Type 2 Diabetes Mellitus in Indonesia
Zainuddin, Z., Abdullah, A. Z., Jafar, N., Suriah, S., Nursalam, N., Darmawansyah, D., Syahrul, S., Wahiduddin, W., Widiantoro, W., & Mallongi, A. (2023) · Pharmacognosy Journal · doi:10.5530/pj.2023.15.68 · Cited by 14
Challenges in Women with Diabetes During the COVID-19 Pandemic
Priya, G., Bajaj, S., Grewal, E., Maisnam, I., Chandrasekharan, S., & Selvan, C. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.2.100 · Cited by 11
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study
Khunti, K. K., HERTZ, C. L., Husemoen, L. L. N., Mocevic, E., Nordsborg, R. B., Piltoft, J. S., & Bain, S. C. (2021) · Diabetic Medicine · doi:10.1111/dme.14697 · Cited by 9
Statistics: Can We Prove an Association for a Rare Complication?
Hopwood, M. B. (1993) · Regional Anesthesia The Journal of Neural Blockade in Obstetrics Surgery & Pain Control · doi:10.1136/rapm-00115550-199318061-00009 · Cited by 9
Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_16_23 · Cited by 8
Factors associated with prolonged poor glycemic control in type 2 diabetes mellitus (T2DM) patients followed in the Department of Internal Medicine at the Yalgado Ouedraogo teaching hospital, Ouagadougou (Burkina Faso)
Traoré, S., Guira, O., Zoungrana, L., Sagna, Y., Bognounou, R., B. Paré, C., Dabourou, D. L., Séré, L., Zemba, D., Dembélé, L. S., et al. (2021) · Open Journal of Internal Medicine · doi:10.4236/ojim.2021.111001 · Cited by 8
Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys
Liao, Y., Ma, A., Wang, Z., Zhou, Y., Liu, L., Zhang, N., Zhang, L., Prud’homme, G. J., & Wang, Q. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106218 · Cited by 8
The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open‐label, randomized trial
Liu, X., Yang, W., Liu, J., Huang, X., Fang, Y., Ming, J., Lai, J., Fu, J., Ji, Q., & Wang, L. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13483 · Cited by 8
Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus
Kolarš, B., Minaković, I., Grabovac, B., Živanović, D., & Mijatović, V. (2024) · Biomedical Papers · doi:10.5507/bp.2024.009 · Cited by 12
Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Dharmalingam, M., Sharma, S. K., Prakash, V., Maiti, A., Kumar, R., Murthy, L. S. S., Balamurugan, R., Maheshwari, S., Kethavath, S. N., Ogale, D., et al. (2024) · Cureus · doi:10.7759/cureus.58115 · Cited by 8
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Ha, K. H., Shin, S., Na, E., & Kim, D. J. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14363 · Cited by 8
A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country
Zaghloul, N., Awaisu, A., Mahfouz, A., Alyafei, S., & Elewa, H. F. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01464-x · Cited by 9
Red Blood Cell Lifespan < 74 Days Can Clinically Reduce Hb1Ac Levels in Type 2 Diabetes
Zhou, S., Dong, R., Wang, J., Zhang, L., Bai, Y., Shao, X., Bai, P., Zhang, R., Ma, Y., & Yu, P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101738 · Cited by 8
Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
Kim, D. J., Sheu, W. H., Chung, W., Yabe, D., Ha, K. H., Nangaku, M., Tan, E. C., Node, K., Yasui, A., Lei, W., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13959 · Cited by 8
Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit
Al‐Saleh, Y., Busaidi, N. A., Dahi, W. A. A., Almajnoni, M., Mohammed, A. S., Alshali, K. Z., Alshamiri, M. Q., Sifri, S. A., Arafah, M., Chan, S. P., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02529-7 · Cited by 10
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Y., Xu, X.-Z., Liu, J., Wang, P.-Y., Wang, X., Feng, H., Liu, C., & Han, X. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03324-6 · Cited by 9
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model
Yuan, S., & Wu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1201818 · Cited by 11
Case study of semaglutide and cardiovascular outcomes: An application of the Causal Roadmap to a hybrid design for augmenting an RCT control arm with real-world data
Dang, L. E., Fong, E., Tarp, J. M., Clemmensen, K. K. B., Ravn, H., Kvist, K., Buse, J. B., van der Laan, M. J., & Petersen, M. L. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.656 · Cited by 11
Self-citation
Diabetic Kidney Disease in Post-Kidney Transplant Patients
Pham, N.-Y. T., Cruz, D., Marin, L. M., Ravender, R., & García, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030793 · Cited by 8
The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective
Kurevija, T., Šojat, D., Bosnić, Z., Mujaj, B., Canecki-Varžić, S., & Majnarić, L. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061617 · Cited by 9
Unraveling the molecular pathogenesis of Type 2 Diabetes and its impact on female infertility: A bioinformatics and systems biology approach
Andlib, N., Prabha, S., & Thakur, S. C. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108987 · Cited by 8
Streamlined Clinical Management Pathways May Reduce Major Amputations in Patients with Chronic Limb Threatening Ischaemia: A Prospective Cohort Study with Historical Controls
Houghton, J. S. M., Meffen, A., Gray, L. J., Payne, T. J., Haunton, V. J., Davies, R., Sayers, R. D., Nduwayo, S., Black, I., Nickinson, A. T. O., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2024.09.005 · Cited by 8
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase‐4 inhibitor plus low‐dose metformin: A multicenter, prospective, randomized, open‐label, parallel‐group comparison study ( MEGMI study)
Takahashi, A., Nomoto, H., Yokoyama, H., Yokozeki, K., Furusawa, S., Oe, Y., Kameda, R., Kawata, S., Miyoshi, A., Nagai, S., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16150 · Cited by 10
Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
Ghosh, S. K., Mukhopadhyay, P., Pandey, P., Chatterjee, P., & Pandit, K. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120973653 · Cited by 8
Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic–Cardio–Renal Perspective for the Primary Care Physician
Mehta, R., Pichel, D., Chen-Ku, C. H., Raffaele, P. M., Durán, A. M., Padilla, F., Álvarez, J. J. A., Gil, J. E. C., Gómez‐Mesa, J. E., Giorgi, M. A., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00961-4 · Cited by 8
Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes
Pen, C. L., Bauduceau, B., Ansolabehere, X., Troubat, A., Bineau, S., Ripert, M., & Dejager, S. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.12.009 · Cited by 8
Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study
Santos‐Pardo, I., Lagerqvist, B., Ritsinger, V., Witt, N., Norhammar, A., & Nyström, T. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.011 · Cited by 8
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
Zimner‐Rapuch, S., Divino, V. M., Norrbacka, K., Boye, K. S., Lebrec, J., Rosilio, M., DeKoven, M., & Guerci, B. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01055-5 · Cited by 9
Investigating the effect of an education programme on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery
Hitchen, S. A., Lan, N. S. R., Ali, U., Hort, A. L., Larbalestier, R. I., Yeap, B. B., & Fegan, P. G. (2021) · Internal Medicine Journal · doi:10.1111/imj.15393 · Cited by 8
The challenge of choosing in cardiovascular risk management
Hoogeveen, R. M., Hanssen, N. M. J., Brouwer, J., Mosterd, A., Tack, C. J., Kroon, A. A., de Borst, G. J., ten Berg, J. M., Trier, T. J. V., van Lennep, J. E. R., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01599-y · Cited by 9
Which BMI for Diabetes Patients is Better? From the View of the Adipose Tissue Macrophage-Derived Exosome
Liu, X., Chu, H., Ji, Y., Bosnjak, Z., Ao, H., & Li, T. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s345890 · Cited by 9
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Kwan, A. Y. M., Gerstein, H. C., Basile, J., Xavier, D., Maldonado, J. M., Raha, S., & Кониг, М. (2022) · Diabetes Care · doi:10.2337/dc21-1160 · Cited by 8
Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.005 · Cited by 8
Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait
Alowayesh, M. S., Aljunid, S. A., Al-Adsani, A. M., Alessa, T., Alattar, A., & Alroudhan, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268495 · Cited by 9
Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials
Li, H., Yang, A., Zhao, S., Chow, E., Javanbakht, M., Li, Y., Lin, D., Xu, L., Zang, D., Wang, K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080953 · Cited by 8
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
Shao, H., Alsaleh, A. J. O., DEX, T. A., Lew, E., & Fonseca, V. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01300-5 · Cited by 8
How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients
Zaina, A., Prencipe, N., Golden, E., Berton, A. M., Arad, E., Ali, A., Shehadeh, J., Kassem, S., & Ghigo, E. (2023) · Endocrine · doi:10.1007/s12020-023-03352-4 · Cited by 8
The Influence of Sildenafil–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice
Pușcașu, C., Ungurianu, A., Șeremet, O. C., Andrei, C., Mihai, D. P., & Negreș, S. (2023) · Medicina · doi:10.3390/medicina59081375 · Cited by 8
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107803 · Cited by 8
An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100082 · Cited by 8
Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III , randomized, open‐label, controlled trial
Feng, W., Chen, W., Jiang, S., Du, L., & Zhu, D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14392 · Cited by 8
Switching the basal insulin to insulin glargine 300 U/ ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety
Seufert, J., Wiesli, P., Fritsche, A., Anderten, H., Pegelow, K., Pscherer, S., & Pfohl, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14549 · Cited by 8
Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC
Bloomgarden, Z. T., & Handelsman, Y. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100007 · Cited by 8
Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial
Schechter, M., Leibowitz, G., & Mosenzon, O. (2020) · Annals of Translational Medicine · doi:10.21037/atm-2020-117 · Cited by 8
Positioning newer drugs in the management of type 2 diabetes
Prattichizzo, F., & Ceriello, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00022-x · Cited by 8
Treating Diabetes to Prevent Stroke
Kernan, W. N., & Inzucchi, S. E. (2021) · Stroke · doi:10.1161/strokeaha.120.032725 · Cited by 9
Diabetes mellitus progression in β-thalassaemia major patients: The impact of iron overload
Mahgoub, E., Qannita, R. A., Alalami, A., Shehadat, O. A., Almahmoud, R., Dib, A., Hajji, A. A., Hajji, A. A., Alkhaja, F., Dewedar, H., et al. (2024) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_39_23 · Cited by 7
Acute Pancreatitis Likely Due to Semaglutide
Hughes, K., Sumaruth, Y. R. K., Mohammed, E., & Bakshsingh, V. S. (2024) · Cureus · doi:10.7759/cureus.69844 · Cited by 8
Effectiveness of patient-centred care in self-management of type 2 diabetes: a systematic review and meta-analysis
Cheng, Z., Xiao, Q., Xu, Y., Tan, L., Qu, W., Shen, W., & Luo, Y. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12539-6 · Cited by 7
Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri‐menopausal women
Lim, B. S. Y., Chen, M., Li, H., & Li, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16442 · Cited by 7
Safety and efficacy of glucagon-like peptide 1 receptor agonists in solid organ transplant recipients with diabetes mellitus: a systematic review and meta-analysis
Usman, M., Yu, H., Chen, X., Zhan, Y., Lai, C., & Xu, K. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.271 · Cited by 7
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
Verma, S., Fainberg, U., Husain, M., Rasmussen, S., Rydén, L., Ripa, M. S., & Buse, J. B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14360 · Cited by 7
Self-citation
Effect of metformin therapy on muscle mass and strength in patients with and without diabetes. Meta-analysis of 15 studies
Sokolova, A. V., Klimova, A. V., Драгунов, Д. О., & Arutyunov, G. P. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4331 · Cited by 9

Authors: Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
Affiliations: University of North Carolina at Chapel Hill (US)
Harvard University (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
University of Copenhagen (DK)
Università Cattolica del Sacro Cuore (IT)
Universitair Ziekenhuis Leuven (BE)
Duke University (US)
University of Leicester (GB)
Corresponding author: Davies, Melanie J.
ORCID: Buse, John B.
Wexler, Deborah J.
Tsapas, Apostolos
Rossing, Peter
Mingrone, Geltrude
Mathieu, Chantal
D’Alessio, David A.
Davies, Melanie J.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2019-12-19
Volume: 43
Issue: 2
Pages: 487-493
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dci19-0066
PMC: PMC6971782
OpenAlex: W4253996779
Cited by: 1,192
References: 21
Citations by year: 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
FWCI: 155.76
Type: journal article
Language: en
Update notices: correction (2020-07-01)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/content/license (vor, 32 d)
Locations: Diabetes Care (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
Lirias (submittedVersion)
PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Funders: American Diabetes Association
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks